Point72 Asset Management
FATE icon

Point72 Asset Management’s Fate Therapeutics FATE Stock Holding History

Point72 Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51.7K Sell
43,119
-1,484,867
-97% -$1.81M ﹤0.01% 3658
2025
Q4 		$1.5M Buy
+1,527,986
New +$1.83M ﹤0.01% 2653
2024
Q2 		– Sell
-1,584,300
Closed -$11.6M – 2025
2024
Q1 		$11.6M Sell
1,584,300
-1,904,863
-55% -$11.8M 0.03% 660
2023
Q4 		$13M Buy
3,489,163
+3,415,762
+4,654% +$8.06M 0.03% 597
2023
Q3 		$156K Buy
73,401
+63,265
+624% +$210K ﹤0.01% 1832
2023
Q2 		$48.2K Buy
+10,136
New +$55.9K ﹤0.01% 1613
2020
Q4 		– Sell
-151,564
Closed -$6.06M – 977
2020
Q3 		$6.06M Sell
151,564
-175,272
-54% -$6.12M 0.03% 522
2020
Q2 		$11.2M Buy
+326,836
New +$9.74M 0.07% 306
2020
Q1 		– Sell
-782,783
Closed -$15.3M – 875
2019
Q4 		$15.3M Sell
782,783
-397,306
-34% -$6.31M 0.08% 304
2019
Q3 		$18.3M Buy
1,180,089
+586,589
+99% +$11.2M 0.11% 238
2019
Q2 		$12M Buy
593,500
+93,500
+19% +$1.68M 0.06% 349
2019
Q1 		$8.79M Buy
+500,000
New +$7.89M 0.04% 429

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management's FATE Position: Q1 2026 in Review

Point72 Asset Management reduced its Fate Therapeutics (FATE) stake by 97% in Q1 2026, selling an estimated $1.81M and leaving 43,119 shares worth $51.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3658.

Point72 Asset Management first reported a position in FATE in Q1 2019 and has held it in 12 quarters since. The position peaked at $18.3M in Q3 2019. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Point72 Asset Management held 43,119 shares of Fate Therapeutics worth $51.7K as of Q1 2026.
  • Point72 Asset Management sold 1,484,867 Fate Therapeutics shares in Q1 2026, an estimated $1.81M.
  • Fate Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3658 holding.
  • Point72 Asset Management first reported a position in Fate Therapeutics in Q1 2019 and has held it in 12 quarters since.
  • Point72 Asset Management's Fate Therapeutics position peaked at $18.3M in Q3 2019.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.